Leerink Partnrs Analysts Lift Earnings Estimates for DexCom

DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of DexCom in a note issued to investors on Friday, February 14th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will earn $0.31 per share for the quarter, up from their prior forecast of $0.30. The consensus estimate for DexCom’s current full-year earnings is $1.69 per share. Leerink Partnrs also issued estimates for DexCom’s Q2 2025 earnings at $0.51 EPS and FY2029 earnings at $3.67 EPS.

Several other research firms have also commented on DXCM. Sanford C. Bernstein increased their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Raymond James reduced their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and increased their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $99.06.

DexCom Trading Up 1.6 %

NASDAQ:DXCM opened at $90.53 on Monday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a market cap of $35.36 billion, a price-to-earnings ratio of 54.21, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The firm has a 50-day moving average price of $82.65 and a two-hundred day moving average price of $75.62.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%.

Hedge Funds Weigh In On DexCom

A number of large investors have recently added to or reduced their stakes in DXCM. Versant Capital Management Inc purchased a new position in DexCom in the 4th quarter worth $25,000. Private Trust Co. NA raised its position in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the period. Optiver Holding B.V. purchased a new position in DexCom in the 4th quarter worth $33,000. TD Private Client Wealth LLC raised its position in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares during the period. Finally, Larson Financial Group LLC raised its position in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock worth $3,309,794 in the last three months. 0.30% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.